Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00644189 · BASELINE

Baseline characteristics

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma · Source last updated 2023-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      30
    units
    Participants
groups
  1. description
    Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles. Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
    id
    BG000
    title
    Clofarabine Phase I
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          47
          upper Limit
          88
          value
          62
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          15
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          15
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          30
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          1
          upper Limit
          7
          value
          1
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Number of prior regimens
    unit Of Measure
    number of prior regimens
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          7
        title
        follicular lymphoma (FL)
      2. measurements
        1. group Id
          BG000
          value
          6
        title
        small lymphocytic lymphoma (SLL)
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        diffuse large B-cell lymphoma (DLBCL)
      4. measurements
        1. group Id
          BG000
          value
          7
        title
        marginal zone lymphoma (MZL)
      5. measurements
        1. group Id
          BG000
          value
          6
        title
        mantle cell lymphoma (MCL)
      6. measurements
        1. group Id
          BG000
          value
          0
        title
        T-cell lymphoma (TCL)
      7. measurements
        1. group Id
          BG000
          value
          1
        title
        lymphoplasmacytic lymphoma (LPL)
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Histologies
    unit Of Measure
    Participants
population Description
Phase I participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      30
    units
    Participants
groups
  1. description
    Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles. Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
    id
    BG000
    title
    Clofarabine Phase I
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          47
          upper Limit
          88
          value
          62
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          15
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          15
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          30
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          1
          upper Limit
          7
          value
          1
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Number of prior regimens
    unit Of Measure
    number of prior regimens
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          7
        title
        follicular lymphoma (FL)
      2. measurements
        1. group Id
          BG000
          value
          6
        title
        small lymphocytic lymphoma (SLL)
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        diffuse large B-cell lymphoma (DLBCL)
      4. measurements
        1. group Id
          BG000
          value
          7
        title
        marginal zone lymphoma (MZL)
      5. measurements
        1. group Id
          BG000
          value
          6
        title
        mantle cell lymphoma (MCL)
      6. measurements
        1. group Id
          BG000
          value
          0
        title
        T-cell lymphoma (TCL)
      7. measurements
        1. group Id
          BG000
          value
          1
        title
        lymphoplasmacytic lymphoma (LPL)
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Histologies
    unit Of Measure
    Participants
population Description
Phase I participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice